076 - The New Move: Treating Tardive Dyskinesia - a podcast by Sean P. Kane, PharmD; Khyati Patel, PharmD

In this episode, we discuss two new agents (valbenazine and deutetrabenazine) -- the first of their kind to receive FDA approval to manage tardive dyskinesia most commonly associated with antipsychotic use.

Further episodes of HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast

Further podcasts by Sean P. Kane, PharmD; Khyati Patel, PharmD

Website of Sean P. Kane, PharmD; Khyati Patel, PharmD